Abstract
Objective: To explore the function of p42.3 in gastric carcinoma.
Methods: We summarized the intricate regulation of p42.3 in gastric carcinoma from several aspects, namely, the structure features, the expression level, its regulation on cell cycle and EMT, its relationship with miR-29a as well as the optimal feedback circuit involved in. Results: We addressed the complex functions of p42.3 in regulating EMT, migration, invasion, proliferation and the optimal regulation network in GC, as well as the significant up/down-stream signal molecules involved in the pathway. We have also illuminated that miR-29a can inhibit cell proliferation and block the cell cycle, at least in part, via the repression of p42.3. Conclusion: In short, p42.3 might serve as a potential therapeutic target in the treatment of GC.Keywords: p42.3, gastric carcinoma, cell cycle, EMT, miR-29a, therapeutic target.
Letters in Drug Design & Discovery
Title:p42.3 in Gastric Carcinoma: A Novel Biomarker and Promising Therapeutic Target
Volume: 14 Issue: 10
Author(s): Hui Jing, Lu-Lu Wei, Fu-Chun Huo, Xin Ren, Jun-Nian Zheng*Dong-Sheng Pei*
Affiliation:
- Department of pathology, Xuzhou Medical University, Xuzhou 221000, China, 209 Tongshan Road, Xuzhou, Jiangsu,China
- Department of pathology, Xuzhou Medical University, Xuzhou 221000, China, 209 Tongshan Road, Xuzhou, Jiangsu,China
Keywords: p42.3, gastric carcinoma, cell cycle, EMT, miR-29a, therapeutic target.
Abstract: Objective: To explore the function of p42.3 in gastric carcinoma.
Methods: We summarized the intricate regulation of p42.3 in gastric carcinoma from several aspects, namely, the structure features, the expression level, its regulation on cell cycle and EMT, its relationship with miR-29a as well as the optimal feedback circuit involved in. Results: We addressed the complex functions of p42.3 in regulating EMT, migration, invasion, proliferation and the optimal regulation network in GC, as well as the significant up/down-stream signal molecules involved in the pathway. We have also illuminated that miR-29a can inhibit cell proliferation and block the cell cycle, at least in part, via the repression of p42.3. Conclusion: In short, p42.3 might serve as a potential therapeutic target in the treatment of GC.Export Options
About this article
Cite this article as:
Jing Hui, Wei Lu-Lu , Huo Fu-Chun, Ren Xin , Zheng Jun-Nian *, Pei Dong-Sheng*, p42.3 in Gastric Carcinoma: A Novel Biomarker and Promising Therapeutic Target, Letters in Drug Design & Discovery 2017; 14 (10) . https://dx.doi.org/10.2174/1570180814666170306121357
DOI https://dx.doi.org/10.2174/1570180814666170306121357 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Expanding Appreciation of the Role Chemokine Receptors Play in Cancer Progression
Current Pharmaceutical Design Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent
Current Cancer Drug Targets Membrane Permeable Lipophilic Cations as Mitochondrial Directing Groups
Current Topics in Medicinal Chemistry Emerging Strategies and Challenges for Controlled Delivery of Taxanes: A Comprehensive Review
Current Drug Metabolism Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer
Current Vascular Pharmacology Mechanosensitive Ion Channels as Drug Targets
Current Drug Targets - CNS & Neurological Disorders In Vitro Regulatory Effect of Epididymal Serpin CRES on Protease Activity of Proprotein Convertase PC4/PCSK4
Current Molecular Medicine A Brief Evaluation of Tumor Imaging in Mice with 99mTc-glucarate Including a Comparison with 18F-FDG
Current Radiopharmaceuticals Scope of Nanotechnology-based Radiation Therapy and Thermotherapy Methods in Cancer Treatment
Current Cancer Drug Targets Current State of the Art of New Tubulin Inhibitors in the Clinic
Current Clinical Pharmacology Omega-3 Polyunsaturated Fatty Acids and Cancer
Anti-Cancer Agents in Medicinal Chemistry Alphaviruses and their Derived Vectors as Anti-Tumor Agents
Current Cancer Drug Targets A Simple, Efficient and Environmentally Benign Synthetic Protocol for the Synthesis of Spirooxindoles Using Choline Chloride-Oxalic Acid Eutectic Mixture as Catalyst/Solvent System
Combinatorial Chemistry & High Throughput Screening Inhibition of Autophagy Strengthens Celastrol-Induced Apoptosis in Human Pancreatic Cancer In Vitro and In Vivo Models
Current Molecular Medicine Cancer Immunotherapy: The Role Regulatory T Cells Play and What Can be Done to Overcome their Inhibitory Effects
Current Molecular Medicine Differences in Phosphorylated Histone H2AX Foci Formation and Removal of Cells Exposed to Low and High Linear Energy Transfer Radiation
Current Genomics Anticancer Mammalian Target of Rapamycin (mTOR) Signaling Pathway Inhibitors: Current Status, Challenges and Future Prospects in Management of Epilepsy
CNS & Neurological Disorders - Drug Targets Molecular Imaging of Stem Cell Transplantation for Neurodegenerative Diseases
Current Pharmaceutical Design Nanoemulsions for Improved Efficacy of Phytotherapeutics- A Patent Perspective
Recent Patents on Nanotechnology Regulation of HIF-1α at the Transcriptional Level
Current Pharmaceutical Design